文献速递临床试验与 GCP

地塞米松12mg与6mg对重症低氧COVID-19患者无生命支持存活天数的影响

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.
PubMed 文献 · JAMA · 2021-01-01

该多中心随机临床试验纳入1000例需至少10L/min氧疗或机械通气的COVID-19成人患者,比较12mg/d与6mg/d地塞米松用至10天的效果。

要点

  • 重症低氧COVID-19患者中,12mg/d地塞米松未显著增加28天无生命支持存活天数。
  • 28天死亡率12mg组27.1% vs 6mg组32.3%,调整相对风险0.86(99%CI 0.68-1.08)。
  • 严重不良反应包括感染性休克和侵袭性真菌感染,两组分别为11.3%和13.4%。

核心结论

  • 在COVID-19伴严重低氧血症患者中,12mg/d地塞米松相比6mg/d未显著增加28天无生命支持存活天数。
  • 试验可能把握度不足,无法识别显著差异。

研究设计与样本

  • 多中心、随机临床试验,2020年8月至2021年5月在欧洲和印度26家医院开展。
  • 纳入1000例确诊COVID-19、需至少10L/min氧疗或机械通气的成人患者,1:1随机接受12mg/d(n=503)或6mg/d(n=497)静脉地塞米松,最长10天。
  • 主要结局为28天无生命支持(有创机械通气、循环支持或肾脏替代治疗)存活天数,并按分层变量调整。

主要发现

  • 28天死亡率12mg组27.1% vs 6mg组32.3%,调整相对风险0.86(99%CI 0.68-1.08)。
  • 90天死亡率12mg组32.0% vs 6mg组37.7%,调整相对风险0.87(99%CI 0.70-1.07)。
  • 严重不良反应(包括感染性休克和侵袭性真菌感染)12mg组11.3% vs 6mg组13.4%,调整相对风险0.83(99%CI 0.54-1.29)。

临床怎么用

  • 对于COVID-19伴严重低氧血症需高流量氧疗或机械通气的成人患者,12mg/d地塞米松未显著优于6mg/d,临床决策需权衡个体情况。

局限性

  • 试验可能把握度不足,无法识别显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease. OBJECTIVE: To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. INTERVENTIONS: Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ≥1 serious adverse reactions at 28 days). RESULTS: Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). CONCLUSIONS AND RELEVANCE: Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021. PMID: 34673895. doi:10.1001/jama.2021.18295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。